48Q Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$1.35 |
| 52 Week Low | US$0.49 |
| Beta | 0.36 |
| 11 Month Change | -5.49% |
| 3 Month Change | 7.65% |
| 1 Year Change | -43.98% |
| 33 Year Change | -87.29% |
| 5 Year Change | n/a |
| Change since IPO | -92.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| 48Q | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.6% | 2.6% | 4.5% |
| 1Y | -44.0% | -16.4% | 13.5% |
Return vs Industry: 48Q underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: 48Q underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| 48Q volatility | |
|---|---|
| 48Q Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 48Q's share price has been volatile over the past 3 months.
Volatility Over Time: 48Q's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 127 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
X4 Pharmaceuticals, Inc. Fundamentals Summary
| 48Q fundamental statistics | |
|---|---|
| Market cap | €98.84m |
| Earnings (TTM) | €15.79m |
| Revenue (TTM) | €504.22k |
6.3x
P/E Ratio196.0x
P/S RatioIs 48Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 48Q income statement (TTM) | |
|---|---|
| Revenue | US$563.00k |
| Cost of Revenue | US$268.00k |
| Gross Profit | US$295.00k |
| Other Expenses | -US$17.34m |
| Earnings | US$17.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 52.40% |
| Net Profit Margin | 3,131.79% |
| Debt/Equity Ratio | 79.4% |
How did 48Q perform over the long term?
See historical performance and comparison